Relation of depot-specific adipose inflammation to insulin resistance in human obesity

SJ Bigornia1, MG Farb2, MM Mott2, DT Hess3, B Carmine3, A Fiscale3, L Joseph4, CM Apovian1 and N Gokce2

BACKGROUND: A low-grade state of adipose tissue inflammation associated with obesity has been linked to mechanisms of systemic metabolic dysfunction. However, the relation of clinical phenotypes to depot-specific inflammation has not been well examined in human obesity.

OBJECTIVE: To characterize the inflammatory status of subcutaneous and visceral fat depots, as assessed by tissue presence of macrophage crown-like structures (CLS) as a hallmark of chronic inflammation, and determine the relation of systemic insulin resistance to inflammatory abnormalities in subcutaneous and visceral fat.

METHODS: We collected adipose tissue simultaneously from subcutaneous and visceral (omental and mesenteric) depots in 92 obese participants (age 42 ± 11 years; BMI ≥ 30 kg m⁻²) during planned bariatric surgery. Using immunohistochemistry, we categorized individuals as CLS⁺ or CLS⁻ based on the presence or absence, respectively, of macrophage CLS in subcutaneous (CLSs), omental (CLSö) and mesenteric (CLSm) adipose depots.

RESULTS: The majority of participants exhibited adipose tissue inflammation manifest by the presence of CLS (CLS⁺) in both subcutaneous and intra-abdominal visceral depots. CLS status in subcutaneous fat was highly sensitive and modestly specific for inflammation of visceral fat. In multivariable models, plasma insulin and homeostatis model assessment levels were positively associated with CLS⁺ status in all depots independent of age, waist circumference, BMI and type 2 diabetes, and worsened with the increasing number of adipose regions involved.

CONCLUSIONS: In severely obese participants, systemic insulin resistance is linked to adipose inflammation in both subcutaneous and visceral depots. The findings suggest that examination of subcutaneous regions that are more easily accessible by transcutaneous biopsy may prove useful in clinical studies designed to investigate adipose phenotypes in relation to human disease.

Keywords: inflammation; obesity; insulin resistance

INTRODUCTION
Clinical studies consistently demonstrate a link between obesity and increased risk for developing insulin resistance and type 2 diabetes (T2DM). The most recent national data show that the majority of adults and a third of children in the US are overweight or obese. Experts now predict that 165 million Americans (at least 50% of adults) will be obese by 2030 leading to a major public health burden and cost. While increased adiposity is associated with metabolic and cardiovascular risks, a growing body of evidence suggests that regional adiposity with selective accumulation of intra-abdominal visceral fat may be more closely linked to disease phenotypes than subcutaneous deposition.

A key mechanism in the pathogenesis of insulin resistance linked to obesity relates to adipose tissue inflammation that has been well demonstrated in experimental animal models and now gaining recognition in clinical human disease. Inflammatory changes in fat tissue appear to be driven by infiltration of adipose tissue macrophages that support a chronic state of inflammation strongly implicated in mechanisms of whole body metabolic dysregulation. We and others have shown that macrophage accumulation in subcutaneous fat in a characteristic histopathological pattern consisting of crown-like structures (CLS) is associated with altered adipose tissue gene expression, cytokine overproduction, systemic insulin resistance and vascular endothelial dysfunction in obese humans. These data support the growing paradigm that both adipose tissue quality and quantity may be relevant to disease mechanism in human obesity. Although subcutaneous fat has been more extensively studied owing to its easier access for clinical investigation, few studies have simultaneously related findings to visceral depots. Thus, our primary objective was to determine whether the inflammatory status of subcutaneous fat as assessed by the presence of macrophage CLS relates to the state of inflammation in visceral fat. Additionally, we sought to determine whether systemic insulin resistance relates more closely to abnormalities in subcutaneous versus visceral reserves in obese humans.

SUBJECTS AND METHODS
Participants
We consecutively enrolled obese (BMI ≥ 30 kg m⁻²) adult men and women, age ≥ 18 years scheduled for gastric bypass surgery at the Boston Medical Center. The patient population was specifically composed of subjects with severe long-standing obesity. Preoperative dietary regimens...
Adipose tissue collection and immunohistochemistry

In 92 obese individuals, approximately 1 cm pieces of adipose tissue were collected intra-operatively from three separate depots (subcutaneous, omental and mesenteric) by the surgeon during the initial stages of planned gastric bypass surgery. Biopsies were secured from regions deemed medically safe by the operating surgeon based on personal experience and were uniformly the same for each patient. Visceral fat was secured from the free edges of the greater omentum and the mesenteric appendices epiploicae of the transverse colon. The subcutaneous fat removed intraoperatively represented the same anatomic layer that would be accessed by a transcutaneous biopsy procedure lateral to the umbilicus. All the tissue samples were immediately stored in formalin or promptly frozen in liquid nitrogen to be stored at \(-80\) °C. Each participant provided a single biopsy specimen from each depot for analysis. Immunohistochemical stains were performed in the Department of Anatomic Pathology at the Boston Medical Center as previously described. Infiltration of macrophage cell populations into adipose tissue was characterized using cell-specific stains targeted to CD68 (predilute antibodies from DakoCytomation Corporation, Glostrup, Denmark). All samples were examined by a single pathologist (J.L.) blinded to all clinical data. CLS status was assessed after examination of all fields available per slide at high-power field (HPF) magnification using light microscopy. A CLS was defined as CD68+ macrophage aggregates comprising at least 50% of the circumference circularly surrounding necrotic adipocytes. Subcutaneous, omental and mesenteric fat depots from each participant were dichotomously categorized based on the presence (CLS+) or absence (CLS-) of CLS in fat. In additional analyses, CLS+ depots were characterized as low density (1 CLS per HPF) or high density (≥2 CLS per HPF). An illustration of two adjacent macrophage CLS (high-density CLS) is displayed in Figure 1. Participants were further categorized by depot-specific CLS status in subcutaneous (CLSs) and omental fat depots (CLSo) as follows: (1) CLS+ in all depots, (2) CLSs+ and CLSo+, and (3) CLSs- and CLSo-. The data were similarly analyzed based on CLSs and CLSm (mesenteric) status.

**RESULTS**

The clinical characteristics of all 92 participants (age 42 ± 11 years) that participated in the study are displayed in Table 1. The majority of individuals were women (86%) with longstanding class III obesity (BMI ≥ 40 kg m\(^{-2}\), 78%). Most participants exhibited evidence of impaired insulin sensitivity (HOMA > 2.0, 72%) and over a third had T2DM. For the group as a whole, the prevalence of T2DM was highest in the subcutaneous depot and lowest in the omental region. Most were CLSs+ (n = 0), CLSo+ (n = 2) or CLSm+ (n = 1). The sensitivity of CLSs for CLSo and CLSm status was high (94% and 95%, respectively) with modest specificity (43% and 57%, respectively). The PPV and NPV of CLSs for CLSo and CLSm were 68% and 85%, respectively, and for CLSm values were 85% for both PPV and NPV.

We explored whether CLSs+, CLSo+ and CLSm+ was associated with markers of insulin resistance and glycemic parameters (HOMA, insulin, glucose and HbA1c) in multivariable models adjusted for age, WCR, BMI and T2DM. As shown in Figure 2a-d, CLSs+ was associated with increased HOMA (P = 0.01) and insulin (P = 0.02) but not glucose (P = 0.71) or HbA1c (P = 0.69). The same relationships were evident in the mesenteric depot, where CLSm+ was associated with increased HOMA (P = 0.05) and insulin (P = 0.04) but not glucose (P = 0.60) or HbA1c (P = 0.83). Similarly, CLSo+ was associated with higher HOMA (P = 0.02), insulin (P = 0.02) and positively trended for HbA1c (P = 0.08); while glucose was not different between groups (P = 0.80). When participants without T2DM were analyzed separately (n = 56),
the findings were directionally similar but reached statistical significance \((P<0.05)\) only for the subcutaneous depot (data not shown). There were no hypoglycemic medication-specific effects on CLS status for each depot. Waist circumference remained a significant predictor of HOMA and insulin in all models. Analyses repeated after excluding male participants \((n=13)\) did not alter the results. We performed additional analyses based on CLS density in adipose tissue. As shown in Table 2, a minority \(<20\%\) of adipose depots exhibited high-density CLS \((\geq 2/HPF)\) as illustrated in Figure 1. There were no significant differences in glucose, insulin or HOMA in subjects with low as compared to high CLS density in any adipose depot.

Additionally, we investigated the relation of HOMA to adipose inflammation in analyses combining subcutaneous and omental fat tissue CLS status, adjusted for age, WCR, BMI and T2DM. Among all participants, 17, 23 and 49 subjects

### Table 1. Clinical characteristics

| Characteristic                | Total | Female       | Male          |
|-------------------------------|-------|--------------|---------------|
| Age, years                    | 42 ± 11 | 79 (86)/13 (14) |               |
| Female/male, n (%)            | 44 (10) |               |               |
| BMI \(\geq 40\) kg m\(^{-2}\), n (%) | 72 (78.3) |               |               |
| Waist circumference, cm       | 113 ± 7.2 |               |               |
| Glucose, mg dl\(^{-1}\)       | 97.0 (25.5) |               |               |
| Insulin, ulU ml\(^{-1}\)      | 12.0 (11.0) |               |               |
| HOMA-IR                       | 3.1 (3.0) |               |               |
| HgA1c, %                      | 5.8 (1.3) |               |               |
| Total cholesterol, mg dl\(^{-1}\) | 179 (45) |               |               |
| LDL cholesterol, mg dl\(^{-1}\) | 115 ± 33 |               |               |
| HDL cholesterol, mg dl\(^{-1}\) | 47 ± 12 |               |               |
| Triglycerides, mg dl\(^{-1}\) | 118 ± 61 |               |               |
| Hs-CRP, mg dl\(^{-1}\)       | 4.9 (6.8) |               |               |
| Type 2 diabetic, n (%)        | 36 (39) |               |               |
| Metformin use, n (%)          | 32 (35) |               |               |
| Sulfonylurea use, n (%)       | 10 (11) |               |               |
| Thiazolidinedione use, n (%)  | 8 (9)   |               |               |
| Insulin use, n (%)            | 6 (7)   |               |               |

### Table 2. CLS density by adipose tissue depot

| Depot          | CLS categorization |
|----------------|--------------------|
|                | None \((0)\) | 1/HPF (low density) | \(\geq 2/HPF\) (high density) |
| Subcutaneous   | 20 (21.7) | 56 (60.8) | 16 (17.4) |
| Omental        | 40 (43.5) | 49 (53.3) | 3 (3.3)   |
| Mesentery      | 30 (32.6) | 55 (59.8) | 7 (7.6)   |

Abbreviations: BMI, body mass index; HgA1c, glycated hemoglobin A1c; HOMA-IR, homeostatis model assessment-insulin resistance; Hs-CRP, high-sensitivity C-reactive protein. Data are presented as n (%).

![Figure 2](image-url)
were $\text{CLS}_{s}/\text{CLS}_{o}$, $\text{CLS}_{s}/\text{CLS}_{o}$, and $\text{CLS}_{s}/\text{CLS}_{o}$, respectively. Only three participants were $\text{CLS}_{s}/\text{CLS}_{o}$ and were excluded from these sets of analyses, which did not affect the results. As shown in Figure 3a, HOMA and insulin increased in a graded pattern, with the $\text{CLS}_{s}/\text{CLS}_{o}$ group demonstrating the lowest and $\text{CLS}_{s}/\text{CLS}_{o}$ group exhibiting the highest HOMA and insulin values ($P<0.05$). Analyses were repeated using data from mesenteric depots, and 17, 13 and 59 participants were $\text{CLS}_{s}/\text{CLS}_{o}$ and were excluded from analysis. Owing to small numbers ($n=3$), $\text{CLS}_{s}/\text{CLS}_{o}$ were excluded from analysis. Similar to the omental depot analyses, HOMA and insulin increased across groups with increasing degrees of depot-specific inflammation as shown in Figure 3b. Again, waist circumference remained a significant predictor of HOMA and insulin in all models. Excluding men ($n=13$) from the analyses did not alter the results.

**DISCUSSION**

In this study of severely obese individuals undergoing gastric bypass surgery, we demonstrated that the majority of participants exhibited evidence of adipose tissue inflammation as manifest by the presence of macrophage $\text{CLS}$ ($\text{CLS}^+$) in both subcutaneous and intra-abdominal visceral (omentum and mesenteric) depots. $\text{CLS}^+$ was strongly associated with $\text{CLS}^+$ in each visceral depot with high sensitivity ($\geq94\%$) and modest specificity. Increased HOMA and insulin levels were independently linked to inflammatory activation in all depots and worsened in a graded fashion with increasing number of adipose regions involved. These findings suggest that whole body metabolic dysfunction is linked to qualitative changes in several human adipose stores simultaneously. In this regard, examination of subcutaneous fat that is more easily accessible by transcutaneous biopsy may provide a window into pathophysiological alterations within deeper visceral depots.

To our knowledge this is the first human study that systematically examined the association between $\text{CLS}$ status in subcutaneous adipose tissue (SAT) and two separate visceral adipose tissue (VAT) regions collected from both the omentum and mesentery. Our results in association with other studies using paired subcutaneous and visceral fat samples in humans and mice show that obesity-related macrophage accumulation occurs in multiple adipose regions. While VAT has been shown to differ in inflammatory transcriptome and secretory capacity, ascribing it a profile potentially more pathogenic compared to SAT, studies have largely been in experimental animal models and in vitro conditions. Recent clinical data in fact show that the progression from the lean to obese state is associated with largely parallel alterations in metabolic and immunoregulatory gene expression profiles in both VAT and SAT that correlate with both fat mass and measures of insulin sensitivity. While visceral fat mass is regarded as an important determinant of cardiometabolic risk, evidence from the Framingham Heart Study suggests that both subcutaneous and visceral loads relate to atherogenic biomarkers. Our findings are in line with several other clinical studies showing a clear association between inflammation in VAT and systemic insulin resistance. Additionally, we provide novel data by demonstrating concordant inflammatory abnormalities as defined by $\text{CLS}$ status in VAT and SAT in human obesity. Considering the high degree of difficulty in securing visceral fat samples from human participants, our findings suggest that inflammation in VAT may serve as a reasonable proxy of inflammatory status in VAT, lending support to the notion that significant clinical information may well be learned by qualitative analysis of SAT in relation to systemic disease. Our novel data by demonstrating concordant inflammatory macrophage populations in mechanistically linked to the development of insulin resistance. A direct role of adipose immune activation in impaired insulin metabolism in humans is also growing recognition. Adipose macrophage density and adipose mRNA CD68 expression correlate with insulin resistance and impaired glucose tolerance that decrease with weight loss. Adipose tissue macrophages express cytokines such as TNF-$\alpha$ and interleukins that have direct roles in mediating insulin resistance. In particular, accumulation of macrophages in patterns of $\text{CLS}$ aggregating around necrotic adipocytes as a sign of chronic tissue inflammation is associated with diseased clinical phenotypes including metabolic dysfunctions and proatherothrombotic vascular abnormalities manifest as impaired endothelial function. Our prior work has demonstrated that inflammatory activation of adipose stores is much more heterogeneous than in animal models, as obese individuals with reduced inflammation display favorable cardiometabolic profiles that are polarized toward a lean phenotype, despite their significant excess fat burden. Although the temporal relationship of depot-specific inflammation in the initial stages of weight gain are unknown, we demonstrate that both SAT and VAT exhibit histopathological abnormalities that are linked to insulin resistance in advanced human obesity.

**Figure 3.** (a, b) Relation of plasma measures of insulin resistance and glycemic parameters to adipose inflammation by combined analyses of (a) subcutaneous-omentum and (b) subcutaneous-mesenteric $\text{CLS}$ status. Data are adjusted for age, WCR, BMI and prevalent T2DM. Data are presented as mean ± s.e., *P* < 0.05 or **P** = 0.05 for comparisons with the $\text{CLS}_{s}/\text{CLS}_{o}$ or $\text{CLS}_{s}/\text{CLS}_{o}$ groups. ln = natural logarithm.
regardless of visceral depot sampled, had higher HOMA and plasma insulin compared with the ‘double negatives’ (CLS− and CLS−/CLS−). Mixed phenotypes of CLS+, and CLS+/CLS−, displayed intermediate values, suggesting that both depots likely incrementally contribute to mechanisms of insulin resistance. We found no difference in plasma HbA1c and glucose between the various CLS groups, likely due to treatment-bias effects of hypoglycemic agents in diabetic participants. Our overall findings were directionally similar but relatively underpowered when individuals with diabetes were excluded from the analyses. We demonstrated that waist circumference remained a significant independent predictor of HOMA and insulin after adjustment for potential confounders including age, BMI and CLS status, supporting the notion that several different factors relating to adipose tissue quality, quantity and regional distribution are all relevant to shaping clinical disease phenotypes.37,39,40

Our present study has several limitations. We relied on a single biopsy site from each depot to minimize the surgical bleeding risk from multiple biopsies, thus it remains plausible that multi-site sampling could have reduced the number of false negatives from a specific region. Moreover, we did not observe a statistically significant relation between CLS density and insulin resistance likely owing to the low number (<20%) of individuals that exhibited abundant tissue CLS based on our classification scheme. However, these limitations are counterbalanced by the relatively large sample size allowing for multivariate analyses in this invasive human study that examined paired samples from two distinct visceral depots, unlike any prior clinical study. We used HOMA as our index variable but acknowledge that it represents an approximation of systemic insulin resistance.11 Euglycemic clamp studies may provide more robust relationships but in our opinion are difficult to perform in such severely obese individuals. We were not able to quantify degree of visceral fat burden using imaging such as CT/MRI as most of our severely obese cohort does not fit into standard imaging machines owing to size constraints. We acknowledge that in lower weight categories, insulin-resistant individuals may exhibit higher visceral fat loads compared with the insulin-sensitive populations. We phenotyped adipose tissue based on macrophage CLS status but understand that this represents only a limited aspect of complex immunoregulatory and functional alterations that develop in adipose reserves in association with weight excess. Lastly, owing to the small number of male participants, we were unable to perform sex-specific analyses. However, our female predominance reflects the general bariatric practice nationally and sex differences in populations that seek weight loss intervention.41

CONCLUSION
In severely obese participants undergoing bariatric surgery, systemic insulin resistance was linked to adipose tissue inflammation in both subcutaneous and visceral depots. Sensitivity of adipose tissue inflammation assessed by the presence of macrophage CLS in SAT for VAT was high (>94%). The findings suggest that subcutaneous inflammatory status may serve as a reasonable indicator of inflammation in visceral depots and that both depots appear to contribute to systemic insulin resistance. We speculate that much can be learned from studying subcutaneous fat that is easily accessible by transcutaneous biopsy, thus permitting serial examination of treatment interventions designed to modulate adipose tissue phenotypes in human clinical studies.

CONFLICT OF INTEREST
Dr Apovian has served on the advisory boards for Allergan, Amylin, Orexigen, Merck, Johnson and Johnson, Arena, and Sanofi-Aventis, and has received research funding from Lilly, Amylin, Pfizer, Sanofi-Aventis, Orexigen, MetaProteomics, and the Dr Robert C and Veronica Atkins Foundation. The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS
Dr Gokce is supported by National Institutes of Health (NHI) Grants R01 HL04213 and P01 HL01857. Dr Farb is supported by NIH Grant T32 HL07224.

REFERENCES
1 Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267–2277.
2 Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
3 Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235 – 241.
4 Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303: 242 – 249.
5 Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815 – 825.
6 Mathieu P, Poirier P, Pibarat P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53: 577 – 584.
7 Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPN J Parenter Enteral Nutr 2008; 32: 645 – 647.
8 Fuentes L, Roszer T, Ricou F. Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediators Inflamm 2010; 2011: 219583.
9 Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793 – 1801.
10 Bremer AA, Devaraj S, Affy A, Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J Endocrinol Metab 2011; 96: E1782–E1788.
11 Apovian CM, Bigornia S, Mott M, Meyers MR, Ullor J, Gagau M et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2010; 28: 1654–1659.
12 Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK et al. Inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010; 59: 1648–1656.
13 Anderson WA, Greene GW, Forse RA, Apovian CM, Istfan NW. Weight loss and health outcomes in African Americans and whites after gastric bypass surgery. Obesity (Silver Spring) 2007; 15: 1455–1463.
14 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
15 Cinti S, Mitchell G, Barbatelli G, Murano I, Cerei E, Falloia E et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and obese people. J Lipid Res 2005; 46: 2347–2355.
16 Harman-Boenim I, Bluher M, Redel H, Stour-Yardney N, Ovadia S, Aivoineo E et al. Macrophage infiltration in omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 2007; 92: 2240–2247.
17 Alkhouri N, Gornicka A, Berk MP, Thapaliai S, Dixon LJ, Kashyap S et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 2009; 285: 3428–3438.
18 Murano I, Barbatelli G, Parisini V, Latini C, Muzzonigro G, Castellucci M et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008; 49: 1562–1568.
19 Hocking SL, Chisholm DJ, James DE. Studies of regional adipose transplantation reveal a unique and beneficial interaction between subcutaneous adipose tissue and the intra-abdominal compartment. Diabetologia 2008; 51: 900–902.
20 Palou M, Priego T, Sanchez J, Rodriguez AM, Palou A, Pico C. Gene expression patterns in visceral and subcutaneous adipose depots in rats are linked to their morphologic features. Cell Physiol Biochem 2009; 24: 547–556.
21 Rytko JM, Wueest S, Schoeneij EL, Konrad D. The portal theory supported by venous drainage-selective fat transplantation. Diabetes 2010; 60: 56–63.
22 Yu R, Kim CS, Kwon BS, Kawada T. Mesenteric adipose tissue-derived monocyte chemotactic protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 2006; 14: 1353–1362.
23 Klimcakova E, Roussel B, Marquez-Quinones A, Kovacova Z, Kovačiková M, Combes M et al. Worsening of obesity and metabolic status yields similar molecular adaptations in human subcutaneous and visceral adipose tissue: decreased metabolism and increased immune response. J Clin Endocrinol Metab 2011; 96: E73–E82.
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation* 2007; **116**: 39–48.

Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. *Circulation* 2007; **116**: 1234–1241.

Depot- and ethnic-specific differences in the relationship between adipose tissue inflammation and insulin sensitivity. *Clin Endocrinol (Oxf)* 2011; **74**: 51–59.

Macrophage gene expression is related to obesity and the metabolic syndrome in human subcutaneous fat as well as in visceral fat. *Diabetologia* 2011; **54**: 876–887.

Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. *J Clin Endocrinol Metab* 2009; **94**: 4619–4623.

Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. *Diabetes* 2006; **55**: 1554–1561.

Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. *Diabetes* 2005; **54**: 2305–2313.

Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* 2005; **54**: 2277–2286.